On February 5, 2025 NuFund Venture Group reported investment in Resolute Science, a preclinical-stage biotechnology company developing a pan-cancer platform targeting tumor-associated macrophages to deliver cytotoxic and radiotherapeutic payloads deep into solid tumors (Press release, Resolute Science, FEB 5, 2025, View Source [SID1234656391]). The funding will support IND-enabling studies for Resolute’s lead asset, RS-5, a MAC-TAC (Macrophage-Targeted Conjugate) carrying an MMAE payload showing profound single-agent anti-cancer efficacy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SAN DIEGO, Feb. 5, 2025 /PRNewswire-PRWeb/ — NuFund, a leading venture group, is thrilled to announce its investment in Resolute Science, Inc., a preclinical-stage biotechnology company developing a novel class of pan-cancer therapeutics for the treatment of aggressive and hard-to-treat solid tumors.

Resolute Science is advancing a pipeline of first-in-class synthetic drug conjugates to deliver targeted cytotoxic and radiotherapeutics deep into tumors. The modular design of its MAC-TAC (Macrophage Targeted Conjugate) platform enables the rapid development of drug candidates carrying a variety of payloads. Resolute’s approach has the potential to overcome the resistance mechanisms associated with cancer-cell targeting therapeutics, delivering more effective and well-tolerated treatments to patients who have run out of options.

Solid tumors have two main cell populations: cancer cells and tumor-associated macrophages (TAMs). TAMs are stable, abundant, non-dividing, and often comprise 30% to 50% of a solid tumor’s mass. By targeting TAMs to receive, process, and distribute payloads throughout the tumor, Resolute aims to improve drug penetration into tumors, reduce off-target toxicity, and deliver greater and more durable anti-cancer efficacy compared to existing treatment options.

"Resolute has developed a potentially breakthrough approach for cancer therapy by targeting a receptor expressed by tumor-associated macrophages to deliver payloads into tumors," explains John Montana, NuFund member and Deal Lead. "Early preclinical data is impressive, and NuFund is proud to help support the company’s drive through the IND-enabling stage and ultimately position them for clinical studies in cancer patients."

As part of the investment, NuFund’s John Montana will join Resolute Science as a board observer. Additionally, James Mackay, a NuFund member and existing Senior Business Advisor to Resolute, will join Resolute’s Board of Directors. While Mackay’s board appointment is independent of this transaction, his deep industry expertise and continued involvement with Resolute further strengthen the company’s leadership as it advances its programs toward the clinic.

"We are grateful for NuFund’s support as we work to translate our therapeutics into the clinic, said Dr. Faith H. Barnett, Founder and CEO of Resolute Science. "NuFund’s financial backing and confidence in Resolute will help us bring new therapies to cancer patients, particularly those with limited or no treatment options. I’m also excited to welcome James to our board. He has been an incredible asset to our company"

This investment will support Resolute Science in advancing its lead asset, RS-5, a MAC-TAC carrying an MMAE payload, through IND-enabling studies and submission. RS-5 has demonstrated potent single-agent anti-cancer efficacy in 16 preclinical studies across multiple tumor models while being well tolerated.